Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Pharmacokinetics and Pharmacodynamics of Ivermectin in Pediatric Dengue Patients (PKIDEN)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03432442
Recruitment Status : Recruiting
First Posted : February 14, 2018
Last Update Posted : January 17, 2019
Sponsor:
Information provided by (Responsible Party):
Mahidol University

Brief Summary:

Design and Outcomes This research study is designed as open-label, sequential dose-escalating clinical trial. There will be two phases of enrollment.

In the first phase, pediatric dengue patients with body weight greater than 30 kg will be recruited. The first six volunteers will be administered with 400 μg/kg every 24 hours for a total of three times. The last six volunteers will be administered with 600 μg/kg every 24 hours for a total of three times.

In the second phase, pediatric dengue patients with body weight between 15 to 30 kg will be recruited. Similar to the first phase, the first six and the last six volunteers will be administered with 400 μg/kg and 600 μg/kg every 24 hours for a total of three times, respectively.

A total of 24 volunteers will be recruited from Faculty of Medicine Siriraj hospitals


Condition or disease Intervention/treatment Phase
Dengue Hemorrhagic Fever Drug: Ivermectin Phase 2

Detailed Description:

The research team has planned to conduct three interim analyses for safety and one final report. The interim analyses will be conducted as follows:

  1. First interim analysis: After the completion of the last volunteer of the group with body weight >30 kg receiving ivermectin 400 μg/kg every 24 hours for a total of three times (i.e. the sixth volunteer).
  2. Second interim analysis: After the completion of the last volunteer of the group with body weight >30 kg receiving ivermectin 600 μg/kg every 24 hours for a total of three times (i.e. the twelfth volunteer).
  3. Third interim analysis: After the completion of the last volunteer of the group with body weight 15 to 30 kg receiving ivermectin 400 μg/kg every 24 hours for a total of three times (i.e. the twelfth volunteer).

The results of each interim analyses will be submitted to DSMB to determine whether the study is safe to be conducted in the next group of volunteers. Additionally, the results of interim analyses and the safety assessments from DSMB will be submitted to all ECs


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 24 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Pharmacokinetics and Pharmacodynamics of Ivermectin in Pediatric Dengue Patients
Actual Study Start Date : September 4, 2018
Estimated Primary Completion Date : July 31, 2019
Estimated Study Completion Date : July 31, 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Dengue
Drug Information available for: Ivermectin

Arm Intervention/treatment
Experimental: Group 1 (6 dengue patients)
Volunteers weighed > 30 kg receiving 400 µg of ivermectin per 1 kg of body weight
Drug: Ivermectin
Ivermectin once every 24 hours for three administrations

Experimental: Group 2 (6 dengue patients)
Volunteers weighed 15 to 30 kg receiving 400 µg of ivermectin per 1 kg of body weight
Drug: Ivermectin
Ivermectin once every 24 hours for three administrations

Experimental: Group 3 (6 dengue patients)
Volunteers weighed > 30 kg receiving 600 µg of ivermectin per 1 kg of body weight
Drug: Ivermectin
Ivermectin once every 24 hours for three administrations

Experimental: Group 4 (6 dengue patients)
Volunteers weighed 15 to 30 kg receiving 600 µg of ivermectin per 1 kg of body weight
Drug: Ivermectin
Ivermectin once every 24 hours for three administrations




Primary Outcome Measures :
  1. Pharmacokinetics of ivermectin in pediatric dengue patients [ Time Frame: 7 days ]
    Blood samples will be collected, and ivermectin plasma concentrations will be measured with High Performance Liquid Chromatography-Tandem Mass Spectrometry (HPLC-MS/MS).


Secondary Outcome Measures :
  1. Pharmacodynamic effects of ivermectin on viral load in plasma of pediatric dengue patients [ Time Frame: 7 days ]
    Blood samples will be collected, and viral load in plasma will be measured with quantitative RT-PCR.

  2. Pharmacodynamic effects of ivermectin on NS1 antigen in plasma of pediatric dengue patients [ Time Frame: 7 days ]
    Blood samples will be collected, and NS1 antigen in plasma will be measured with NS1-ELISA assay.

  3. Viremia clearance [ Time Frame: 7 days ]
    Time between the first drug administration and the point of specimen collection at which viral load becomes undetectable

  4. NS1 antigenemia clearance [ Time Frame: 7 days ]
    Time between the first drug administration and the point of specimen collection at which NS1 antigen becomes undetectable

  5. Occurrences of adverse events [ Time Frame: 7 days ]
    The number of volunteers with any adverse events by the total number of volunteers in the treatment group

  6. Occurrences of abnormal laboratory result [ Time Frame: 7 days ]
    The number of volunteers with any change of laboratory results from normal at baseline to abnormal during the study by the total number of volunteers in the treatment group.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   1 Year to 15 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Aged between 1-15 years 0 day
  2. Weight is equal or greater than 15 kg
  3. History or presence of acute fever within the last 72 hours diagnosed as acute dengue virus infection
  4. Patients who are expected to be able to start the study drug within 72 hours of fever
  5. Written informed consent to enroll in the study is obtained from parents or legal representatives and/or patients.
  6. The test for dengue nonstructural protein 1 is positive, or PCR screening for viral genome is positive
  7. Female patients with history of menarche need to have a negative result for urine pregnancy test, except during a menstrual period.

Exclusion Criteria:

  1. Has significant underlying disease(s) that can affect the study outcome or the study participation may be harmful to patients with those underlying diseases including but not limited to:

    • Kidney disease
    • Thalassemia
    • congenital heart disease
    • epilepsy
    • cerebral palsy Other underlying diseases may result in exclusion depending on the judgement of investigator.
  2. Having developed or showed the following laboratory values, warning signs or signs of severe dengue including:

    • AST and/or ALT levels > 500 IU/L
    • Platelets count < 50,000 cells/mm3
    • Abdominal pain or tenderness
    • Persistent vomiting
    • Clinical fluid accumulation such as pleural effusion, ascites
    • Mucosal bleeding
    • Lethargy/restlessness
    • Liver enlargement >2 cm
    • Increase in Hct concurrent with rapid decrease in platelet count
    • Severe plasma leakage such as dengue shock syndrome, fluid accumulation with respiratory distress
    • Severe bleeding as evaluated by clinician
    • Severe organ involvement including but not limited to acute liver failure, altered level of consciousness (e.g. encephalopathy, encephalitis), seizure or other CNS unusual manifestation, acute renal failure, cardiomyopathy and other unusual manifestation
  3. History of ivermectin allergy or receiving medications that increase gamma-aminobutyric acid (GABA) potentiating activity such as barbiturates, benzodiazepines, sodium oxybate, valproic acid, or receiving medications that prevent p-glycoprotein transport system such as amiodarone, carvedilol, clarithromycin, cyclosporine, erythromycin, itraconazole, ketoconazole, quinidine, ritonavir, tamoxifen, verapamil, amprenavir, clotrimazole, phenothiazines, rifampin, St. John's Wort etc.
  4. Currently receiving immunosuppressive agents such as steroid (except topical steroid), chemotherapeutic agents or have discontinued these medications for less than a month
  5. Having a history of receiving ivermectin within one month
  6. Inability to ingest medications in a form of tablets as informed by patients and their parents or legal representatives

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03432442


Contacts
Layout table for location contacts
Contact: Panisadee Avirutnan, Assoc. Prof. +662 419 6667 panisadee.avi@mahidol.ac.th
Contact: Dumrong Mairiang, PhD dumrongm@gmail.com

Locations
Layout table for location information
Thailand
Faculty of Tropical Medicine Siriraj Hospital Recruiting
Bangkok Noi, Bangkok, Thailand, 10700
Contact: Panisadee Avirutnan, MD    +66 2419 7000 ext 96667    panisadee.avi@mahidol.ac.th   
Contact: Usa Panichpathompong    +66 2419 7000 ext 96667    Jum0311@outlook.com   
Sponsors and Collaborators
Mahidol University
Investigators
Layout table for investigator information
Principal Investigator: Panisadee Avirutnan, Assoc. Prof. Faculty of medicine Siriraj Hospital

Layout table for additonal information
Responsible Party: Mahidol University
ClinicalTrials.gov Identifier: NCT03432442     History of Changes
Other Study ID Numbers: VIR17003
First Posted: February 14, 2018    Key Record Dates
Last Update Posted: January 17, 2019
Last Verified: January 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Severe Dengue
Dengue
Hemorrhagic Fevers, Viral
Arbovirus Infections
Virus Diseases
Flavivirus Infections
Flaviviridae Infections
RNA Virus Infections
Ivermectin
Antiparasitic Agents
Anti-Infective Agents